Financial Information
This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.
| Beta | (1.96) |
|---|---|
| Shares Outstanding | 28.9M |
| Average Volume (10 days) | 501.4K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 1 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Eugene Durenard Director | (2,000) Sell Sep 8, 2021 |
|---|---|
Brian L. Brown Chief Financial Officer | 5,000 Acquire May 24, 2021 |
Dwight H Egan Director, Chief Executive Officer | (5,628) Dispose May 24, 2021 |
Brian L. Brown Chief Financial Officer | (1,524) Dispose May 24, 2021 |
Dwight H Egan Director, Chief Executive Officer | 12,500 Acquire May 24, 2021 |
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
COMPANY
LATEST NEWS RELEASE
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.